Illinois General Assembly

  Bills & Resolutions  
  Compiled Statutes  
  Public Acts  
  Legislative Reports  
  IL Constitution  
  Legislative Guide  
  Legislative Glossary  

 Search By Number
 (example: HB0001)
Search Tips

Search By Keyword

Illinois Compiled Statutes

 ILCS Listing   Public Acts  Search   Guide   Disclaimer

Information maintained by the Legislative Reference Bureau
Updating the database of the Illinois Compiled Statutes (ILCS) is an ongoing process. Recent laws may not yet be included in the ILCS database, but they are found on this site as Public Acts soon after they become law. For information concerning the relationship between statutes and Public Acts, refer to the Guide.

Because the statute database is maintained primarily for legislative drafting purposes, statutory changes are sometimes included in the statute database before they take effect. If the source note at the end of a Section of the statutes includes a Public Act that has not yet taken effect, the version of the law that is currently in effect may have already been removed from the database and you should refer to that Public Act to see the changes made to the current law.

20 ILCS 5170/100-5

    (20 ILCS 5170/100-5)
    (Section scheduled to be repealed on January 1, 2028)
    Sec. 100-5. Creation; members; duties; report.    
    (a) The Special Commission on Gynecologic Cancers is created. Membership of the Commission shall be as follows:
        (1) A representative of the Illinois Comprehensive
    
Cancer Control Program, appointed by the Director of Public Health;
        (2) The Director of Insurance, or his or her
    
designee; and
        (3) 20 members who shall be appointed as follows:
            (A) three members appointed by the Speaker of the
        
House of Representatives, one of whom shall be a survivor of ovarian cancer, one of whom shall be a survivor of cervical, vaginal, vulvar, or uterine cancer, and one of whom shall be a medical specialist in gynecologic cancers;
            (B) three members appointed by the Senate
        
President, one of whom shall be a survivor of ovarian cancer, one of whom shall be a survivor of cervical, vaginal, vulvar, or uterine cancer, and one of whom shall be a medical specialist in gynecologic cancers;
            (C) three members appointed by the House Minority
        
Leader, one of whom shall be a survivor of ovarian cancer, one of whom shall be a survivor of cervical, vaginal, vulvar, or uterine cancer, and one of whom shall be a medical specialist in gynecologic cancers;
            (D) three members appointed by the Senate
        
Minority Leader, one of whom shall be a survivor of ovarian cancer, one of whom shall be a survivor of cervical, vaginal, vulvar, or uterine cancer, and one of whom shall be a medical specialist in gynecologic cancers; and
            (E) eight members appointed by the Governor, one
        
of whom shall be a caregiver of a woman diagnosed with a gynecologic cancer, one of whom shall be a medical specialist in gynecologic cancers, one of whom shall be an individual with expertise in community based health care and issues affecting underserved and vulnerable populations, 2 of whom shall be individuals representing gynecologic cancer awareness and support groups in the State, one of whom shall be a researcher specializing in gynecologic cancers, and 2 of whom shall be members of the public with demonstrated expertise in issues relating to the work of the Commission.
    (b) Members of the Commission shall serve without compensation or reimbursement from the Commission. Members shall select a Chair from among themselves and the Chair shall set the meeting schedule.
    (c) The Illinois Department of Public Health shall provide administrative support to the Commission.
    (d) The Commission is charged with the study of the following:
        (1) establishing a mechanism to ascertain the
    
prevalence of gynecologic cancers in the State and, to the extent possible, to collect statistics relative to the timing of diagnosis and risk factors associated with gynecologic cancers;
        (2) determining how to best effectuate early
    
diagnosis and treatment for gynecologic cancer patients;
        (3) determining best practices for closing
    
disparities in outcomes for gynecologic cancer patients and innovative approaches to reaching underserved and vulnerable populations;
        (4) determining any unmet needs of persons with
    
gynecologic cancers and those of their families; and
        (5) providing recommendations for additional
    
legislation, support programs, and resources to meet the unmet needs of persons with gynecologic cancers and their families.
    (e) The Commission shall file its final report with the General Assembly no later than December 31, 2022 and, upon the filing of its report, is dissolved.
(Source: P.A. 102-4, eff. 4-27-21; 102-674, eff. 11-30-21.)